GLP1R and metabolic dysfunction-associated steatotic liver disease: Semaglutide, a novel GLP-1R agonist, reduces cardiovascular risk (Marso et al., 2016a) and levels of alanine aminotransferase (ALT) and inflammatory markers (Newsome et al., 2019); it is a potential treatment for NAFLD.